Every S-1 that Moleculin Biotech, Inc. (MBRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow MBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBRX filings page.
Moleculin Biotech, Inc. is conducting a reasonable best efforts public offering of up to 4,566,210 shares of common stock, together with Series I common warrants and alternative pre-funded warrants. The registration also covers up to 18,264,840 shares of common stock underlying the pre-funded and common warrants.
The assumed combined public offering price is $2.19 per share (or pre-funded warrant) and accompanying three common warrants, matching the July 27, 2026 Nasdaq closing price. If all securities are sold at this price, net proceeds are estimated at $9.1 million, to advance Annamycin through clinical development and for working capital. Common stock outstanding would increase from 7,100,713 to 11,666,923 shares, with as adjusted net tangible book value of $1.32 per share and immediate dilution of $0.87 per share to new investors.
The offering has no minimum, no escrow and may close with significantly less capital raised, potentially limiting the intended use of proceeds. Common warrants become exercisable only after any required Warrant Stockholder Approval; without such approval they will not be exercisable and will have no value. Interim data from the pivotal MIRACLE Phase 2/3 trial in relapsed/refractory AML showed higher complete remission rates in Annamycin arms versus control, but results are based on a limited sample, are not yet statistically significant and may not predict final outcomes.
Moleculin Biotech, Inc. is registering a reasonable best efforts primary offering of up to 4,566,210 shares of common stock, up to 4,566,210 pre-funded warrants, and 13,698,630 Series I common warrants at an assumed combined price of $2.19 per share or pre-funded warrant plus warrants.
Each share or pre-funded warrant is sold with three common warrants, exercisable at $2.19 for five years beginning on the later of closing or any required Warrant Stockholder Approval; without such approval the common warrants will not be exercisable and will have no value. There is no minimum offering amount, no escrow, and Roth Capital Partners acts as placement agent for a 7% cash fee.
Assuming all securities are sold at the assumed price, Moleculin estimates net proceeds of about $9.1 million, to be used to advance its lead drug Annamycin and for working capital. Shares outstanding would increase from 5,336,350 to 9,902,560, excluding warrant, option and RSU overhang.
The company is conducting the pivotal Phase 2/3 MIRACLE trial in relapsed/refractory AML. A June 2026 interim analysis in 45 patients showed complete remission rates of 43% and 36% in two Annamycin arms versus 12% in control, and composite CR rates of 50% and 57% versus 29%. These results were not statistically significant; the independent data monitoring committee recommended continuing both Annamycin dose arms, and the trial remains designed for 80% power at final analysis. The company states that these interim data may not predict final outcomes and that it will require significant additional financing, beyond this offering, to continue funding its clinical programs.
Moleculin Biotech, Inc. is conducting a reasonable best efforts primary offering of up to 4,566,210 shares of common stock, together with up to 4,566,210 pre-funded warrants, up to 13,698,630 common warrants, and up to 18,264,840 shares underlying those warrants. Each share or pre-funded warrant is offered with three common warrants at an assumed combined price of $2.19.
The company is a late-stage pharmaceutical developer focused on Annamycin (naxtarubicin), a “next‑generation” anthracycline in a pivotal Phase 2/3 MIRACLE trial for relapsed/refractory AML. Interim unblinded results from 45 patients showed higher complete and composite remission rates in both Annamycin arms versus control, but without statistical significance at this stage; the independent monitoring committee recommended continuing the trial.
At the assumed $2.19 price and full take-up, Moleculin projects net proceeds of about $9.1 million, intended mainly to advance Annamycin and for working capital. Common shares outstanding would increase from 5,336,350 to 9,902,560 before any warrant exercises, and new investors would incur immediate book-value dilution.